Bagsvaerd, Denmark

Jorgen Buus Lassen

This inventor holds 1 USPTO granted patent and 3 published patent applications, plus 1 CIPO patent. Top assignee: Saniona A/s. Active years: 2016.

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2016

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Jorgen Buus Lassen: Innovator in Pharmaceutical Compositions

Introduction

Jorgen Buus Lassen is a notable inventor based in Bagsvaerd, Denmark. He has made significant contributions to the field of pharmaceuticals, particularly in the area of combination therapy. His innovative work focuses on enhancing therapeutic efficacy while minimizing side effects.

Latest Patents

Jorgen holds a patent for "Pharmaceutical compositions for combination therapy." This invention relates to the use of pharmaceutical compositions that combine Tesofensine and Metoprolol. The goal of this combination is to prevent the cardiovascular side effects associated with Tesofensine, while maintaining its effectiveness in reducing food intake and promoting body weight loss. He has 1 patent to his name.

Career Highlights

Jorgen is currently associated with Saniona A/S, a company dedicated to advancing innovative therapies. His work at Saniona has allowed him to explore new avenues in pharmaceutical research and development. His expertise in combination therapies has positioned him as a valuable asset in the industry.

Collaborations

Throughout his career, Jorgen has collaborated with talented professionals, including Henrik Bjork Hansen and Morten Grunnet. These collaborations have fostered a creative environment that encourages innovation and the development of groundbreaking therapies.

Conclusion

Jorgen Buus Lassen is a distinguished inventor whose work in pharmaceutical compositions has the potential to significantly impact the treatment of various health conditions. His dedication to innovation and collaboration continues to drive advancements in the field.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…